Open AccessCharacteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
Author(s) -
Kieran Rothnie,
Sandra Joksaite,
Leah Sansbury,
Chris Compton,
Valentina Di Boscio,
Afisi S Ismaila
Publication year - 2022
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s338436
Subject(s) - medicine , lama , exacerbation , copd , inhaler , indacaterol , fluticasone propionate , medical record , dry powder inhaler , corticosteroid , physical therapy , asthma , bronchodilator
Inhaled triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who have poorly controlled symptoms and to reduce the risk of exacerbations. This study assessed the clinical characteristics of new users of single- and multiple-inhaler triple therapy (SITT and MITT) treated in a primary care setting in England.